NCT04487574View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

July 25, 2020

Primary Completion Date

October 29, 2020

Study Completion Date

October 29, 2020

Conditions
SARS-CoV-2 Infection
Interventions
DRUG

XC221

Participants will receive XC221 100 mg 2 times a day during 14 days

DRUG

Placebo

Participants will receive Placebo 2 times a day during 14 days

Trial Locations (5)

197706

"Saint Petersburg State Budgetary Institution of Healthcare City Hospital No. 40 of Kurortny District", Saint Petersburg

199106

"Saint Petersburg State Budgetary Institution of Healthcare City Pokrovskaya Hospital (4th Cardiology Department)", Saint Petersburg

"Saint Petersburg State Budgetary Institution of Healthcare City Pokrovskaya Hospital", Saint Petersburg

346918

"Municipal Budgetary Institution of Healthcare Central City Hospital of Novoshakhtinsk", Novoshakhtinsk

634040

"Regional State Budgetary Institution of Healthcare Medical-Sanitary Unit No. 2", Tomsk

All Listed Sponsors
lead

RSV Therapeutics LLC

INDUSTRY

NCT04487574 - A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19 | Biotech Hunter | Biotech Hunter